SPRY
HEALTHCAREARS Pharmaceuticals Inc
$9.28+0.25 (+2.77%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving SPRY Today?
No stock-specific AI insight has been generated for SPRY yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$6.66$18.90
$9.28
Fundamentals
Market Cap$922M
P/E Ratio—
EPS$-1.74
Dividend Yield—
Dividend / Share—
ROE-0.9%
Profit Margin-2.0%
Debt / Equity—
Trading
Volume3.2M
Avg Volume (10D)—
Shares Outstanding99.3M
SPRY News
20 articles- Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat EstimatesYahoo Finance·May 7, 2026
- ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial ResultsYahoo Finance·May 7, 2026
- Earnings Preview: ARS Pharmaceuticals, Inc. (SPRY) Q1 Earnings Expected to DeclineYahoo Finance·May 6, 2026
- How The ARS Pharmaceuticals (SPRY) Narrative Is Shifting With Fresh Analyst Models And ApprovalsYahoo Finance·May 2, 2026
- ARS Pharmaceuticals, Inc. (SPRY) Soars 7.1%: Is Further Upside Left in the Stock?Yahoo Finance·Apr 23, 2026
- Northland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation DriverYahoo Finance·Apr 17, 2026
- neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)Yahoo Finance·Apr 15, 2026
- ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) LabelYahoo Finance·Mar 27, 2026
- ARS Pharmaceuticals Q4 Earnings Call HighlightsMarketbeat·Mar 9, 2026
- ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earnings Call Highlights: Strong Market Entry and ...Yahoo Finance·Mar 9, 2026
- ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue EstimatesYahoo Finance·Mar 9, 2026
- ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) CommercializationYahoo Finance·Mar 9, 2026
- ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Yahoo Finance·Mar 2, 2026
- ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming ConferencesYahoo Finance·Feb 23, 2026
- How Recent Regulatory Twists Are Reframing The Story For ARS Pharmaceuticals (SPRY)Yahoo Finance·Feb 18, 2026
- Got $300? 2 Biotech Stocks to Buy and Hold ForeverMotley Fool·Feb 16, 2026
- ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific MeetingYahoo Finance·Feb 10, 2026
- How Investors May Respond To ARS Pharmaceuticals (SPRY) Expanding EURneffy Pediatric Use Across EuropeYahoo Finance·Feb 3, 2026
- EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kgYahoo Finance·Feb 2, 2026
- California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency UseYahoo Finance·Jan 21, 2026
All 20 articles loaded
Price Data
Open$9.05
Previous Close$9.03
Day High$9.57
Day Low$9.05
52 Week High$18.90
52 Week Low$6.66
52-Week Range
$6.66$18.90
$9.28
Fundamentals
Market Cap$922M
P/E Ratio—
EPS$-1.74
Dividend Yield—
Dividend / Share—
ROE-0.9%
Profit Margin-2.0%
Debt / Equity—
Trading
Volume3.2M
Avg Volume (10D)—
Shares Outstanding99.3M
About ARS Pharmaceuticals Inc
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine aerosol with absorption technology for patients and their families at risk of severe allergic reactions to food, medication, and insect stings. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—